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It is well-documented that post-translational modifica-
tion (PTM) events, such as glycosylation, play an impor-
tant role in antibody-dependent cell-mediated
cytotoxicity (ADCC) [1,2]. In current technological pro-
cesses, monoclonal antibody (mAb) production is widely
achieved using heterologous hybridoma systems or
genetic engineering using various non-human cell lines
as expression host. As a consequence, PTMs generated
from non-human cell lines may differ from their human
counterparts, resulting in diminished antibody efficacy,
aberrant folding and adverse immunogenic response.
Therefore, the use of human partner cell lines to gener-
ate “fully human” mAbs is beneficial as it circumvents
functional complications associated with non-human
cell lines.
A human cross-lineage hybrid cell line was developed
in our laboratory as a candidate partner for immortalisa-
tion of rare primary human antigen-specific B lympho-
cytes using binary electrical cell hybridisation technique
which has been developed in house. This novel partner
cell line is a tri-hybrid of IL-4 secreting Th2 lympho-
blast derived from a patient with acute lymphoblastic
leukaemia (T), CD20
+ B lymphoblast, also derived from
a patient with acute lymphoblastic leukaemia (W), and
IL-6 secreting peripheral blood-derived CD14
+ mono-
cyte (M). The selection of cell phenotypes used to create
the tri-hybrid was based on factors known to maintain
and promote antibody production.
The resulting tri-hybrid (WTM) displayed characteris-
tics of mixed CD phenotypes with the majority of cells
being CD20
+ (95%) with co-expression of CD4
+ (54%)
and CD14
+ (24%). It secreted IL-4, IL-6, IL-8 and GM-
CSF but was negative for IL-1A, IL-1B, IL-2, IL-5, IL-10,
IL-12, IL-13 and IL-17. The cell line did not express the
tumour suppressor protein, p53, and neither did it
secrete immunoglobulins (Ig)/ Ig chains nor were they
expressed on the surface.
WTM cells were then used as a fusion partner with
primary antigen-experienced CD19
+ B cells which had
been isolated from peripheral blood, activated in vitro,
and the resultant hybrids were sorted for IgM
+ and IgG
+ expression. 100% hybridisation success rate was
achieved using a binary electrical cell hybridisation tech-
nique and the number of resulting stable hybrids varied
from 48% to 78% depending on the phenotype of B lym-
phocytes used in experiments. 23% to 68% of those
stable hybrids secreted Ig with production ranging
between 0.2 to 1.2 ìg/10
6 cells (Table 1). Cytokine
screening of some of the Ig producing hybrids revealed
a cytokine profile which was inherently different to that
of the WTM partner cell line. The Ig producing hybrids
concurrently expressed IL-10 and GM-CSF but not IL-
4, IL-6 or IL-8. These hybrids were also positive for
TGF-â, RANTES, MIP, MCP and MDC.
In conclusion, major advantages of our method
involve the rapid generation of stable Ig producing
hybrids from a small B lymphocyte population size (50
cells) and the elimination of conventional laborious
screening methods for hybrids and Ig producing clones.
Thus, when the number of rare antigen-specific B cells
available is a limiting factor in generating hybridoma,
EBV transfection or direct sequencing, binary electrical
B lymphocyte hybridisation with WTM cells can provide
a very attractive approach for the generation of stable
hybrid cell lines producing monoclonal antibodies.
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Table 1 Success rate of stable hybrid generation and Ig
producing hybrids
Event Success rate,
Hybridisation 100 (%) of attempts
Stable hybrids 48 (%) of hybridised
Ig producing hybrids 23 (%) of stable hybrids
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